pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic
Impact Therapeutics
Partner Therapeutics Limited
Partner Therapeutics is a pharma organization headquartered in GB. Primary therapeutic focus areas include Breast Cancer, NSCLC, synchronous oligo-metastatic, Solid Tumors, ER-positive/HER2-negative early breast cancer,
Company details
- Status
- Public
- HQ
- 1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
- Founded
- 2010
- Employees
- 8
- Programs
- 12
- Drugs
- 26
- Patents
- 0
LIBTAYO 350 mg concentrate for solution for infusion.
Phase 3 · small molecule · Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%
LIBTAYO 350 mg concentrate for solution for infusion. for Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1% is a Phase 3 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Internal code ETOP 27-23 ARCH
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Partner Therapeutics Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%
- Status
- active
- Trials
- 1